CELCUITY INC

Company Overview

Celcuity Inc. is a Healthcare sector, Biotechnology company focused on developing targeted cancer therapies, led by gedatolisib, an intravenous PI3K and mTOR inhibitor designed to block the PAM pathway. Its lead commercial opportunity is in hormone receptor-positive, HER2-negative advanced breast cancer, with additional development in metastatic castration-resistant prostate cancer and other solid tumors. The company remains clinical-stage and pre-revenue, but it has made meaningful progress with Phase 3 trials, including positive results in the PIK3CA wild-type cohort of VIKTORIA-1 and an NDA that has already been accepted by the FDA with Priority Review. Celcuity’s business is highly dependent on clinical execution, regulatory milestones, and eventual commercialization, while also relying on third-party manufacturing and a licensed asset from Pfizer.

Executive Compensation Practices

For a Biotechnology company like Celcuity, executive compensation is likely to be heavily weighted toward long-term incentives and milestone-based pay rather than current revenue or earnings, since the company is still pre-revenue and posting large operating losses. The most relevant performance drivers for pay are likely clinical development milestones, FDA filing and approval progress, successful trial enrollment and readouts, and commercialization readiness, especially for gedatolisib in breast cancer. The sharp rise in R&D, G&A, and stock-based compensation suggests a compensation program that may include meaningful equity grants to retain leadership through multiple high-risk regulatory and launch milestones. In this sector, boards often use equity awards, option grants, and milestone bonuses to align management with long-duration value creation tied to trial success and approval.

Insider Trading Considerations

Insider trading activity in a Biotechnology company like Celcuity is often closely influenced by binary catalysts, including Phase 3 data releases, NDA acceptance, PDUFA dates, and financing events. Because the company is approaching a potential approval decision and has multiple readouts expected in 2026, insiders may face heightened blackout periods and stricter trading limitations around these material events. The recent capital raises, debt issuance, and continued cash burn also make financing-sensitive periods important to monitor, as insiders may be reluctant or restricted from trading while major funding or launch decisions are pending. For researchers and day traders, the most important context is that trading patterns in this name may cluster around trial announcements, FDA interactions, and commercialization milestones rather than routine operational updates.